ENA 2014 Scientific programme

Tuesday 18 November 2014

Opening Remarks

13:00 - 13:15

Scientific Chair - EORTC
Chair: J.C. Soria (France)

Scientific Co-Chair - NCI
Chair: L.J. Helman (USA)

Scientific Co-Chair - AACR
Chair: J.A. Engelman (USA)

Michel Clavel Lecture: Rational combination therapies for cancer

13:15 - 14:00

Rational combination therapies for cancer
Speaker: R. Bernards (Netherlands)

Keynote Lecture: Immunocheckpoints - Gateway to Immunotherapy

14:00 - 14:45

Immunocheckpoints - Gateway to Immunotherapy
Speaker: D. Chen (USA)
Plenary Session 1: Is the Genomic Landscape Changing the Outcome for Cancer Patients?

15:15 - 17:30 Auditorium

Chair: R. Stupp (Switzerland)
Chair: J. Tabernero (Spain)

15:15 Overview of academic precision medicine trials
Speaker: P. Bedard (Canada)

15:35 Lessons from SAFIR01 trial
Speaker: F. André (France)

15:55 Translating gene expression signatures into clinical practice: prospects and challenges in the context of 'next-generation medicine'
Speaker: R. Dienstmann (USA)

16:15 Genomic characterization of cancer: Case studies
Speaker: E.R. Mardis (USA)

16:35 Screening Patients for Efficient Clinical Trial Access (SPECTA)
Speaker: D. Lacombe (Belgium)

16:55 ORAL PRESENTATION: Feasibility of large-scale genomic testing to facilitate enrollment on genomically-matched clinical trials

17:10 General discussion
Speaker: J. Tabernero (Spain)

17:15 Faster execution of clinical trials - has bioinformatics the solution?
Speaker: G. McVie (Italy)
Wednesday 19 November 2014

Workshop 1: Management of Toxicity of Molecular Targeted Agents

08:00 - 09:45  Auditorium

Chair: J.C. Soria (France)
Chair: P. Bedard (Canada)
08:00  Cardiac toxicities with MOA and TKI
Speaker: S. Ederhy (France)
08:20  Digestive and endocrine toxicities of checkpoint inhibitors
Speaker: N. Chaput (France)
08:40  Non neutropenic infective complications of PI3-AKT-m-TOR pathway inhibitors
Speaker: U. Banerji (United Kingdom)
09:00  Ocular Toxicity of MEK inhibitors and other targeted therapies
Speaker: J.P. Velazquez-Martin (Canada)
09:20  Discussion

Workshop 2: Cancer metabolism

08:00 - 09:45  Room 117

Chair: C. Van Dang (USA)
Chair: G. Hardie (United Kingdom)
08:00  AMPK – opposing the metabolic changes in tumour cells
Speaker: G. Hardie (United Kingdom)
08:20  IDH1/IDH2
Speaker: D.P. Schenkein (USA)
08:40  Targeting MYC-driven Glutaminolysis
Speaker: C. Van Dang (USA)
09:00 Identification of novel inhibitors of GLUT1 as potent cancer cell-killing agents
   Speaker: A. Wise (United Kingdom)
09:20 Discussion

Workshop 3: “Liquid Biopsies” in Solid Tumours

10:15 - 12:00 Auditorium

Chair: K. Dhingra (USA)
Chair: A. Bardelli (Italy)
10:15 Application of CTC detection technologies in oncology clinical trials
   Speaker: J.S. De Bono (United Kingdom)
10:35 Cancer mutation and transcriptome analysis in exosomes
   Speaker: J. Skog (USA)
10:55 cfDNA for detection of actionable cancer mutations
   Speaker: C. Caldas (United Kingdom)
11:15 Precision medicine for colorectal cancers: liquid biopsies and preclinical models
   Speaker: A. Bardelli (Italy)
11:35 Discussion

Workshop 4: Translational Research with Immunostimulatory monoclonal antibodies

10:15 - 12:00 Room 117

Chair: J. Tabernero (Spain)
Chair: I. Melero (Spain)
10:15 The making of new immunotherapy agents
   Speaker: A. Korman (USA)
10:35 Translational research of combined immunotherapies
   Speaker: I. Melero (Spain)
11:05 Biomarkers for new immunotherapies
   Speaker: M. Callahan (USA)
11:25 The interface of immunomodulation and vaccines  
Speaker: A. Van Elsas (Netherlands)

11:45 Discussion

Professional Advancement session: “Navigating Your Career with Confidence”: A Professional Advancement Session  
Organized by the AACR-Women in Cancer Research (WICR) Council

12:15 - 13:15 Room 117

Welcome  
Chair: P. LoRusso (USA)

Keynote Lecture  
Speaker: S. Galbraith (United Kingdom)

Panel Discussion  
S. Galbraith (United Kingdom)  
M. Foti (USA)  
F. Meunier (Belgium)

Closing remarks and evaluation  
Chair: P. LoRusso (USA)

Posters in the Spotlight session

12:15 - 12:45 Exhibition Hall

Moderator: R. Plummer (United Kingdom)

The following abstract nos will be discussed: 364 (P144), 161 (P155), 422 (P155)

There will be a stage with a large plasma screen set up in the hall. Three poster presenters have been invited to present their poster for 5 minutes, following which, there will be a 5 minute question and answer with the moderator and audience.
Plenary Session 2: Proffered Paper Session

13:15 - 15:20 Auditorium

Chair: C.L. Arteaga (USA)
Chair: R. Plummer (United Kingdom)

13:15 Target validation as a crucial bottleneck in cancer drug discovery
Speaker: P. Workman (United Kingdom)

13:35 ORAL PRESENTATION: Safety and early evidence of activity of a first-in-human phase I study of the novel cancer stem cell (CSC) targeting antibody OMP-52M51 (anti-Notch1) administered intravenously to patients with certain advanced solid tumors

13:50 ORAL PRESENTATION: Afuresertib (GSK2110183), an oral AKT kinase inhibitor, in combination with carboplatin and paclitaxel in recurrent ovarian cancer

14:05 ORAL PRESENTATION: Activity of galeterone in castrate-resistant prostate cancer (CRPC) with C-terminal AR loss: Results from ARMOR2

14:20 ORAL PRESENTATION: Mechanism based targeted therapy for hereditary leiomyomatosis and renal cell cancer (HLRCC) and sporadic papillary renal cell carcinoma: interim results from a phase 2 study of bevacizumab and erlotinib
14:35 **ORAL PRESENTATION: Imaging in cancer immunology: Phenotyping of multiple immune cell subsets in-situ in FFPE tissue sections**
J.R. Mansfield, C. Slater, C. Wang, K. Roman, C.C. Hoyt, R.J. Byers (USA)

14:50 **LATE BREAKING ABSTRACT: Clinical safety and activity in a phase I trial of AG-120, a first in class, selective, potent inhibitor of the iIDH1-mutant protein, in patients with IDH1 mutant positive advanced hematologic malignancies**

15:00 **LATE BREAKING ABSTRACT: The identification of potent and selective inhibitors of oncogenes in medullary thyroid carcinoma and lung adenocarcinoma disease models**

15:10 **Discussion Late Breaking Abstracts**
Discussant: C.L. Arteaga (USA)

**Plenary Session 3: Oncolytic Viruses**

16:00 - 17:50 Auditorium

Chair: K. Harrington (United Kingdom)
Chair: L.J. Helman (USA)

16:00 **T-VEC for the treatment of melanoma: Are we ready for prime time?**
Speaker: H. Kaufman (USA)

16:20 **Poliovirus oncolytic immunotherapy of glioblastoma**
Speaker: M. Gromeier (USA)

16:40 **Measles and vesicular stomatitis virus strains as novel oncolytic platforms**
Speaker: E. Galanis (USA)

17:00 **Challenges in clinical development of oncolytic viruses**
Speaker: K. Harrington (United Kingdom)

17:20 **LATE BREAKING ABSTRACT: Initial Report of a** 3LBA
First-In-Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640
J. Infante, M. Patel, D. Von Hoff, A. Brenner, C. Rubino, W. McCulloch, V. Zhukova-Harrill, M. Parsey (USA)
17:30 LATE BREAKING ABSTRACT: A Phase 1 study of first-in-class microRNA-34 mimic, MRX34, in patients with hepatocellular carcinoma or advanced cancer with liver metastasis
M. Beg, A. Brenner, J. Sachdev, M. Borad, J. Cortes, R. Tibes, Y. Kang, A. Bader, J. Stoudemire, S. Smith, S. Kim, D. Hong (USA)
17:40 Discussion Late Breaking Abstracts
Discussant: L.J. Helman (USA)

Thursday 20 November 2014

Plenary Session 4: Antibody-Based Therapies (ADC and others)

08:00 - 10:00 Auditorium

Chair: A. Tolcher (USA)
Chair: N. Gökbuget (Germany)

08:00 Antibody mediated payload delivery: Cautionary lessons from 20 years of clinical trials
Speaker: A. Tolcher (USA)

08:20 Challenging the dogmas: Clinical efficacy of SN38 conjugated antibodies in solid tumours
Speaker: D.M. Goldenberg (USA)

08:40 Targeted alpha particle therapy for hematologic malignancies
Speaker: J. Jurcic (USA)

09:00 Bispecific T-cell engaging antibodies in acute leukemia – Recent advances and future challenges
Speaker: N. Gökbuget (Germany)

09:20 ORAL PRESENTATION: Pre-clinical and...
translational pharmacology, pharmacokinetics and pharmacodynamics for a humanized anti-OX40 antibody MOXR0916, a T-cell agonist in the treatment of solid tumors

09:35 **ORAL PRESENTATION: A phase 1 study of KTN3379, a human anti-ErbB3 monoclonal antibody in patients with advanced cancers**
P. LoRusso, T. LaVallee, L. Kimmel, C. Lubeski, R. Gedrich, C. Sidor (USA)

09:50 **General discussion**
Speaker: A. Tolcher (USA)

**Plenary Session 5: Epigenetic Targets**

10:30 - 12:30 Auditorium

Chair: K. Helin (Denmark)
Chair: T. Helleday (Sweden)

10:30 **Histone demethylases and methyltransferases as novel targets for cancer therapeutics**
Speaker: K. Helin (Denmark)

10:50 **DOT1 and EZH2 targeted therapies**
Speaker: R. Copeland (USA)

11:10 **Targeting non-oncogene addiction with MTH1 inhibitors**
Speaker: T. Helleday (Sweden)

11:30 **ORAL PRESENTATION: A novel synthetic lethal interaction between the histone mark H3K36me3 and checkpoint kinases**
S.X. Pfister, E. Markkanen, Y. Jiang, S. Sarkar, V. D'Angiolella, G. Dianov, A.J. Ryan, T.C. Humphrey (United Kingdom)

11:45 **ORAL PRESENTATION: Novel anti-tumor activity of targeted LSD1 inhibition by GSK2879552**

12:00 **LATE BREAKING ABSTRACT: Results of a first-in-**
man phase I trial assessing OTX015, an orally available BET-bromodomain (BRD) inhibitor, in advanced hematologic malignancies

12:10 LATE BREAKING ABSTRACT: Phase 1 first-in-human study of the enhancer of zeste-homolog 2 (EZH2) histone methyl transferase inhibitor E7438 as a single agent in patients with advanced solid tumors or B cell lymphoma
V. Ribrag, J.C. Soria, L. Reyderman, R. Chen, P. Salazar, N. Kumar, G. Kuznetsov, H. Keilhack, L.H. Ottesen, A. Italiano (France)

12:20 Discussion Late Breaking Abstracts
Discussant: T. Helleday (Sweden)

Posters in the Spotlight session

12:45 - 13:15 Exhibition Hall
Moderator: E. Calvo (Spain)

The following abstract nos will be discussed: 140 (P134)*, 41 (P035)*, 195 (P189)
* pending acceptance

There will be a stage with a large plasma screen set up in the hall. Three poster presenters have been invited to present their poster for 5 minutes, following which, there will be a 5 minute question and answer with the moderator and audience.

Plenary Session 6: Proffered Paper Session

13:30 - 15:35 Auditorium
Chair: E. Calvo (Spain)
Chair: J. Doroshow (USA)
13:30 ORAL PRESENTATION: A phase I dose-finding study of BI 853520, a potent and selective inhibitor of focal adhesion kinase (FAK), in Japanese and Taiwanese patients with advanced or metastatic solid tumors

13:45 ORAL PRESENTATION: Homologous recombination deficiency (HRD) score and niraparib efficacy in high grade ovarian cancer

14:00 ORAL PRESENTATION: Updated clinical and preliminary correlative results of ARIEL2, a PHASE 2 study to identify ovarian cancer patients likely to respond to rucaparib

14:15 ORAL PRESENTATION: Phase I study of panobinostat and fractionated stereotactic re-irradiation therapy (FSRT) for recurrent high grade gliomas

14:30 ORAL PRESENTATION: Results of a phase I, open-label, multicentre study to assess the safety, tolerability, pharmacokinetics and preliminary antitumour activity of AZD9150 in patients with advanced/metastatic hepatocellular carcinoma

14:45 ORAL PRESENTATION: Genomic analysis identifies novel drivers and targetable pathways in inflammatory breast cancer patient samples
D.M. Moran, K. Rao, P. Bacon-Trusk, K. Pry, V. Weigman, V. Velculescu, M. Cristofanilli, S. Bacus (USA)
15:00 **ORAL PRESENTATION:** Phase I trial evaluating the antiviral agent Cidofovir in combination with chemoradiation in cervical cancer patients: A novel approach to treat HPV related malignancies

15:15 **LATE BREAKING ABSTRACT:** Phase 1 dose-expansion study of AMG 900, a pan-aurora kinase inhibitor, in adult patients with advanced taxane-resistant solid tumors

15:25 **Discussion Late Breaking Abstract**
Discussant: J. Doroshow (USA)

**Plenary Session 7: Novel Mechanisms for Drug Resistance**

16:00 - 17:50 Auditorium

Chair: U. Banerji (United Kingdom)
Chair: S.A. Courtneidge (USA)

16:00 **Genomic instability, diversity and resistance during cancer evolution**
Speaker: N. McGranahan (United Kingdom)

16:20 **Immune-scape to PD1/PDL1 blockade**
Speaker: D. Chen (USA)

16:40 **EMT as mechanism of resistance to TKI**
Speaker: J. Thiery (Singapore)

17:00 **The landscape of kinase fusions in cancer**
Speaker: C. Lengauer (USA)

17:20 **ORAL PRESENTATION:** Overcoming drug-resistance in multiple myeloma by XPO1 inhibitor combination therapy
J. Turner, J. Dawson, S. Grant, K. Shain, C. Cubitt, Y. Dai, L. Zhoui, M. Kauffman, S. Shacham, D. Sullivan (USA)

17:35 **LATE BREAKING ABSTRACT:** Activity of the PARP inhibitor olaparib in ATM-deficient gastric cancer: from preclinical models to the clinic
D. Hodgson, H. Mason, L. Oplustilova, C. Harbron, X.
Friday 21 November 2014

Plenary Session 8: Targeting RAS and Other Driver Oncogenes

11:00 - 13:00 Auditorium

Chair: J.A. Engelman (USA)
Chair: M. Barbacid (Spain)

11:00 Targeting KRAS driven lung and pancreatic adenoicarcinoma
Speaker: M. Barbacid (Spain)

11:20 Systematic interrogation of vulnerabilities in KRAS driven cancers
Speaker: W. Hahn (USA)

11:40 Targeting synthetic lethal partners of KRAS
Speaker: J. Luo (USA)

12:00 ORAL PRESENTATION: Clinical acquired resistance to combined RAF/EGFR or RAF/MEK inhibition in BRAF mutant colorectal cancer (CRC) patients through MAPK pathway alterations

12:15 LATE BREAKING ABSTRACT: Antitumor activity of ASP8273, an irreversible mutant selective EGFR-TKI, in NSCLC patients with tumors harboring
EGFR activating mutations and T790M resistance mutation


12:35 LATE BREAKING ABSTRACT: Phase I study of the selective BRAFV600inhibitor encorafenib (LGX818) combined with cetuximab and with or without the a-specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF mutant colorectal cancer

12:45 Discussion Late Breaking Abstracts
Discussant: J.A. Engelman (USA)